Seiwert Summarizes Immunotherapy Advances in Head and Neck Cancer – OncLive
OncLive |
Seiwert Summarizes Immunotherapy Advances in Head and Neck Cancer
OncLive The treatment landscape of head and neck cancer has changed significantly over the past year. With the approval of pembrolizumab (Keytruda) in August 2016 and nivolumab (Opdivo) in November 2016, immunotherapy has become a key player in patient … |
